G1 Therapeutics Inc Stock Price, News & Analysis

G1 Therapeutics, Inc. (GTHX), a biopharmaceutical company, announced the granting of inducement stock options for 63,500 shares and 38,000 restricted stock units (RSUs) to six new employees under the Amended and Restated 2021 Inducement Equity Incentive Plan. The stock options have a ten-year term and are exercisable at $5.39 per share, with vesting occurring over four years. The RSUs also vest over four years. This action aligns with Nasdaq Listing Rule 5635(c)(4) aimed at attracting new talent to the company.

G1 Therapeutics, Inc. (GTHX) announced a webcast and conference call for a corporate and financial update on May 4, 2022, at 8:30 a.m. ET. The event will provide insights into the company's first quarter performance. G1 Therapeutics focuses on developing therapies for cancer and is known for its product, COSELA (trilaciclib). The call can be accessed through a dedicated phone line and will also be available via a webcast on the company's website, ensuring transparency with investors.

G1 Therapeutics, a commercial-stage oncology company, announced participation in the 21st Annual Needham Virtual Healthcare Conference. CEO Jack Bailey and CMO Raj Malik will engage in a fireside chat on April 13, 2022, at 11:00 AM EDT. The event will be accessible via live webcast on their website. G1 Therapeutics focuses on developing next-generation cancer therapies, including COSELA™ (trilaciclib), with a robust clinical pipeline aimed at treating various solid tumors. For more information, visit www.g1therapeutics.com.

G1 Therapeutics (GTHX) announced the issuance of inducement stock options for 25,800 shares and 11,200 restricted stock units (RSUs) to four new employees, under the Amended and Restated 2021 Inducement Equity Incentive Plan. Each stock option is priced at $8.02, which was the closing price on the grant date, and they vest over four years. The plan allows G1 to grant equity awards to new employees as an incentive, enhancing recruitment efforts in the competitive oncology sector.

G1 Therapeutics (GTHX) presented a study at the NCCN 2022 Annual Conference revealing significant findings on myelosuppression in patients with extensive-stage small-cell lung cancer treated with chemotherapy. The retrospective analysis of 3,277 patients showed that trilaciclib reduced grade ≥ 3 myelosuppressive hematologic adverse events by 50% and all-cause hospitalizations by 74% compared to chemotherapy alone. The study highlights the potential of trilaciclib to enhance patient outcomes and decrease healthcare resource utilization.

G1 Therapeutics, Inc. (Nasdaq: GTHX) announced the grant of stock options and restricted stock units (RSUs) to four new employees under its Sales Force Inducement Equity Incentive Plan. The inducement comprises 10,800 shares of stock options and 8,800 RSUs, aimed at attracting talent. The stock options are exercisable at $10.05 per share, the closing price on the grant date, March 1, 2022. Each stock option has a ten-year term with a four-year vesting schedule. G1 Therapeutics continues to focus on developing therapies for cancer treatment, including its first product, COSELA™.

G1 Therapeutics, a commercial-stage oncology company, announced its participation in two investor conferences in March 2022. On March 8, CEO Jack Bailey will join a New Drug Launches panel at the Cowen Health Care Conference. Following this, on March 15, Bailey and CMO Raj Malik will engage in a fireside chat at the Roth Conference. Both events will be accessible via webcast on the company's events page. G1 is focused on enhancing cancer treatments with its product COSELA and has a robust pipeline for various solid tumors.

G1 Therapeutics reported total revenues of $5.8 million for Q4 2021, including $4.4 million from COSELA sales. The company completed its COSELA sales team and anticipates initial results from its Phase 3 colorectal cancer trial in early Q1 2023. G1 initiated two Phase 2 trials to explore trilaciclib’s immune mechanism. Cash reserves stood at $221.2 million, sufficient to fund operations into 2024. However, Q4 2021 net loss rose to $40 million, higher than the previous year.

G1 Therapeutics, Inc. (GTHX) will host a webcast and conference call on February 23, 2022, at 8:30 a.m. ET to discuss its corporate and financial update for Q4 and full year 2021. The call can be accessed domestically at (866) 763-6020 or internationally at (409) 216-0626 using conference code 5256086. G1 is focused on advancing therapies for cancer, notably through COSELA™ (trilaciclib), and has a diverse clinical pipeline targeting various solid tumors like colorectal and lung cancers.